FindTrial
Sign In

Effects of Fei Gan Granules Combined with Conventional Western Medicine on Short-term Traditional Chinese Medicine Symptoms in Mild to Moderate COVID-19 Patients: A Prospective Clinical Observational Study

A multicenter clinical efficacy evaluation of FeiGan Granule in alleviating short-term symptoms of COVID-19 infection and mechanism research based on multi group strategy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000099
Enrollment
Unknown
Registered
2025-01-14
Start date
2024-02-16
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

TCM group:Feigan granules + standard medication
Control group:Standard medication

Sponsors

The First Affiliated Hospital Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 82 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old . gender unlimited; (2) Diagnosed with mild to moderate COVID-19; (3) Contains at least two influenza-like symptoms from fever sore throat and cough.

Exclusion criteria

Exclusion criteria: (1) complicated with serious cardiopulmonary liver and kidney diseases; (2) Pregnant or lactating women; (3) Other proprietary Chinese medicine or decoction with anti-COVID-19 or anti-influenza effect; (4) Can accept or cannot cooperate with the completion of the interviewer.

Design outcomes

Primary

MeasureTime frame
Fever;Cough;Sore throat;—

Secondary

MeasureTime frame
Muscle soreness;reduce diet;Chest distress;dry mouth;—

Countries

China

Contacts

Public ContactQingwei Zhao

The First Affiliated Hospital Zhejiang University School of Medicine

qwzhao@zju.edu.cn+86 135 8806 6886

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026